BioWorld MedTech

Aug. 26, 2010

Canaccord analyst sees robust M&A trends in cardio

The cardiovascular device sector should expect to see M&A activity to be more robust in the next couple of years than it has been in the last 20 to 30 years, according to one analyst who covers this space. (Medical Device Daily) Read More

F&S analyst: Device misuse key in causing medical errors

International report: Elekta's Gamma Knife used for the first time in Australia

Washington roundup: FDA seeks input on four pre-amendments devices

Financings roundup: Healthsense closes growth capital funding round

Deals roundup: Stryker in move to acquire Gaymar for nearly $150M

People in the News

Agreements/contracts: Cerus acquires rights to BioOne's Intercept

Grants roundup: Dynasil company wins $6.2M in DoE grants

Product Briefs

Patent watch: Celera gets gene-detecting patent for heart attack risk

MDD's Ortho Extra

MDD's food for med-tech thought

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....